JPS63227598A - Hexose phosphoric acid ferrous salt, production thereof and iron-providing agent containing said salt - Google Patents
Hexose phosphoric acid ferrous salt, production thereof and iron-providing agent containing said saltInfo
- Publication number
- JPS63227598A JPS63227598A JP6207787A JP6207787A JPS63227598A JP S63227598 A JPS63227598 A JP S63227598A JP 6207787 A JP6207787 A JP 6207787A JP 6207787 A JP6207787 A JP 6207787A JP S63227598 A JPS63227598 A JP S63227598A
- Authority
- JP
- Japan
- Prior art keywords
- ferrous
- salt
- hexose
- iron
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002402 hexoses Chemical class 0.000 title claims abstract description 25
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 title claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title abstract description 16
- 229910000147 aluminium phosphate Inorganic materials 0.000 title abstract description 10
- 150000003839 salts Chemical class 0.000 title description 11
- -1 Hexose phosphoric acid alkaline earth metal salt Chemical class 0.000 claims abstract description 11
- 230000007935 neutral effect Effects 0.000 claims abstract description 9
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 8
- 230000002378 acidificating effect Effects 0.000 claims abstract description 7
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 37
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 30
- 229910019142 PO4 Inorganic materials 0.000 claims description 23
- 239000010452 phosphate Substances 0.000 claims description 23
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 18
- 229910052742 iron Inorganic materials 0.000 claims description 14
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 208000007502 anemia Diseases 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 159000000009 barium salts Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000002244 precipitate Substances 0.000 description 19
- 229910001448 ferrous ion Inorganic materials 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000000921 elemental analysis Methods 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000011790 ferrous sulphate Substances 0.000 description 8
- 235000003891 ferrous sulphate Nutrition 0.000 description 8
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 8
- 229940116007 ferrous phosphate Drugs 0.000 description 7
- 229910000155 iron(II) phosphate Inorganic materials 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 229950010772 glucose-1-phosphate Drugs 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010022971 Iron Deficiencies Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000003021 water soluble solvent Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 239000004277 Ferrous carbonate Substances 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000021425 apple cider vinegar Nutrition 0.000 description 1
- 229940088447 apple cider vinegar Drugs 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 description 1
- 235000019268 ferrous carbonate Nutrition 0.000 description 1
- 229960004652 ferrous carbonate Drugs 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 description 1
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- SDEKDNPYZOERBP-UHFFFAOYSA-H iron(ii) phosphate Chemical compound [Fe+2].[Fe+2].[Fe+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O SDEKDNPYZOERBP-UHFFFAOYSA-H 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は新規なヘキソースリン酸第一鉄塩に関し、さら
に詳しくはヘキソースリン酸第一鉄塩、その製造法及び
これを含有する鉄供給剤に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a novel ferrous hexose phosphate, and more particularly to a ferrous hexose phosphate, a method for producing the same, and an iron supplying agent containing the same. Regarding.
鉄は生体内で酸素の運搬、酸化還元機構等に関与し、生
命を維持する為に必要な必須金属である。Iron is an essential metal that is involved in oxygen transport and redox mechanisms within living organisms, and is necessary to sustain life.
この鉄が欠乏すると食欲不振、不定愁訴、貧血、易疲労
感、頭痛、労作時息切れ、顔面蒼白等の症状を示すこと
が知られており、鉄欠乏の原因としては鉄摂取の不足、
鉄喪失の増加、鉄需要の増加、吸収不全などが挙げられ
ている。It is known that iron deficiency causes symptoms such as loss of appetite, irregular complaints, anemia, fatigue, headache, shortness of breath on exertion, and facial pallor.The causes of iron deficiency include insufficient iron intake,
These include increased iron loss, increased iron demand, and malabsorption.
このような鉄欠乏症の治療としては、経口及び静注によ
る鉄供給剤の投与が効果的であることが知られておシ、
そして鉄は二価の第一鉄イオンの形態で十二指腸よシ吸
収される為、鉄供給剤としては、還元鉄、第一鉄イオン
が主として用いられている。具体的には、還元鉄、硫酸
第一鉄、コノ・り酸第−鉄、乳酸第一鉄などが知られて
おシ、このうち、特に、硫酸第一鉄は安価で有効である
ことから、古くから使用されている。しかし、従来−公
知の鉄供給剤には二価の第一鉄イオンが空気中の酸素に
より、十二指腸において吸収されない三価の第二鉄イオ
ンへ酸化されるという問題があった。It is known that oral and intravenous administration of iron-supplying agents is effective for the treatment of iron deficiency.
Since iron is absorbed through the duodenum in the form of divalent ferrous ions, reduced iron and ferrous ions are mainly used as iron supplying agents. Specifically, reduced iron, ferrous sulfate, ferrous phosphate, ferrous lactate, etc. are known, and among these, ferrous sulfate is particularly cheap and effective. , has been used since ancient times. However, conventionally known iron supplying agents have a problem in that divalent ferrous ions are oxidized by oxygen in the air to trivalent ferric ions, which are not absorbed in the duodenum.
したがって、安全性に優れ、酸化されにくい鉄供給剤が
求められていた。Therefore, there has been a need for an iron supplying agent that is highly safe and resistant to oxidation.
本発明者らは、生体内に存在する化合物の鉄塩に関して
鋭意検討した結果、新規化合物であるヘキソースリン酸
第一鉄塩がヘキソースリン酸アルカリ土類金属と中性ま
たは酸性の第一鉄塩の反応によシ合成されること及びこ
のヘキソースリン酸第−鉄が鉄供給剤として有用である
事を見い出し、本発明を完成した。As a result of intensive studies on iron salts of compounds existing in living organisms, the present inventors discovered that a new compound, ferrous hexose phosphate, is a combination of an alkaline earth metal hexose phosphate and a neutral or acidic ferrous salt. The present invention was completed based on the discovery that the hexose ferrous phosphate is useful as an iron supplying agent.
すなわち本発明は、新規化合物であるヘキソースリン酸
第一鉄塩、その製造法及びこれを含有する鉄供給剤を提
供するものである。That is, the present invention provides a novel compound, ferrous hexose phosphate, a method for producing the same, and an iron supplying agent containing the same.
従来、ヘキソースリン酸の金属塩としては、ナトリウム
、カリウム、カルシウム、バリウム、マグネシウムなど
が知られておシ、たとえばグルコース−１−リン酸カル
シウム塩の製造法として、グルコース−１−リン酸と水
酸化カルシウムを反応させる方法（特公昭４３−１０６
２０ ）等が知られている。本発明者らはヘキソースリ
ン酸と水酸化第一鉄を反応させてヘキソースリン酸第一
鉄塩を合成する方法を試みたが、純度良く合成すること
は困難であった。この原因は二価の第一鉄イオンは、酸
性及び中性では酸素による酸化に対して比較的安定であ
るが、アルカリ性では不安定である為によると考えられ
る。Conventionally, sodium, potassium, calcium, barium, magnesium, etc. are known as metal salts of hexose phosphate. For example, as a method for producing calcium glucose-1-phosphate, glucose-1-phosphate and calcium hydroxide are used. (Special Publication No. 43-106)
20) etc. are known. The present inventors attempted a method of synthesizing ferrous hexose phosphate by reacting hexose phosphoric acid with ferrous hydroxide, but it was difficult to synthesize with high purity. This is thought to be because divalent ferrous ions are relatively stable against oxidation by oxygen in acidic and neutral conditions, but are unstable in alkaline conditions.
そこで、本発明者らは、中性のアルカリ土類金属塩と中
性または酸性の第一鉄塩を反応させることによシ、酸化
を抑制しながらヘキソースリン酸第一鉄塩が製造できる
事、及び該反応で副生ずる塩が水に対して難溶性である
ように第一鉄イオンのアニオンを選択すれば、ヘキソー
スリン酸第一鉄塩と副生ずる無機塩と容易に分離できる
事、さらに合成されたヘキソースリン酸第一鉄塩が鉄供
給剤として有用である事を見い出した。Therefore, the present inventors have discovered that ferrous hexose phosphate can be produced while suppressing oxidation by reacting a neutral alkaline earth metal salt with a neutral or acidic ferrous salt. , and if the anion of the ferrous ion is selected so that the salt by-produced in the reaction is poorly soluble in water, the ferrous hexose phosphate salt and the inorganic salt by-produced can be easily separated; It has been found that the synthesized ferrous hexose phosphate is useful as an iron supplying agent.
本発明に係わるヘキソースリン酸第一鉄塩は、ヘキソー
スの一つ以上の水酸基がリン酸基で置換されたリン酸エ
ステルの第一鉄塩であり、たとえハクルコースー１−リ
ン酸、グルコース−６−リン酸、クルコース−１，６−
ゾＩＪン酸、フルクトース−６−リン酸、フルクトース
−１，６−ゾリン酸などの第一鉄塩が挙げられ、このう
ち、鉄供給剤としては、グルコース−１−リ／酸第一鉄
塩グルコース−６−リン酸第一鉄塩がコストのうえから
特に好ましい。The ferrous hexose phosphate salt according to the present invention is a ferrous salt of a phosphate ester in which one or more hydroxyl groups of the hexose are substituted with a phosphoric acid group, such as haculcose-1-phosphate, glucose-6- Phosphoric acid, glucose-1,6-
Examples include ferrous salts such as zoIJ acid, fructose-6-phosphate, and fructose-1,6-zophosphate. Among these, examples of iron-supplying agents include ferrous salts of glucose-1-ly/acid. Ferrous glucose-6-phosphate is particularly preferred from the viewpoint of cost.
出発原料であるヘキソースリン酸アルカ１Ｊ１１ｊ金属
塩のアルカリ土類金属としては、バリウム、カルシウム
などが挙げられるが、好ましくはバリウムである。この
ヘキソースリン酸アルカリ土類金属塩は、ヘキソースリ
ン酸を水酸化アルカリ土類金属塩で中和して得られる。Examples of the alkaline earth metal of the alkali hexose phosphate 1J11j metal salt, which is a starting material, include barium, calcium, etc., but barium is preferred. This alkaline earth metal hexose phosphate is obtained by neutralizing hexose phosphoric acid with an alkaline earth metal hydroxide.
通常０．５〜１０重量％（以下単に「チ」で示す）の水
酸化アルカリ土類金属塩水溶液に１〜２０％のへキソー
スリン酸を滴下、混合し得られる。反応温度は一１０〜
７０℃であ夛、好ましくは１０〜４０℃である。It is usually obtained by dropping 1 to 20% of hexose phosphoric acid to a 0.5 to 10% by weight (hereinafter simply referred to as "ch") aqueous solution of alkaline earth metal hydroxide and mixing. The reaction temperature is -10~
The temperature is 70°C, preferably 10 to 40°C.
他の出発原料である中性または酸性の第一鉄塩としては
、硫酸第一鉄、炭酸第一鉄などが挙げらに対するモル比
はリン酸基に対して１モル以上であり、好ましくは１〜
２モルである。Examples of neutral or acidic ferrous salts that are other starting materials include ferrous sulfate and ferrous carbonate, and the molar ratio of these to the phosphate group is 1 mole or more, preferably 1 mole. ~
It is 2 moles.
ヘキソースリン酸アルカリ土類金属塩と中性または酸性
の第一鉄塩を反応させる溶媒は水が好ましいが、反応を
妨害しない水溶性溶媒であれば共存していてもよい。通
常、ヘキソースリン酸ｇ −鉄塩は、０．５〜１０％の
ヘキソースリン酸アルカリ土類金属水溶液に１〜５０％
の第一鉄塩水溶液を滴下、混合して得られる。反応温度
は一１０〜７０℃であり、好ましくは１０〜４０℃であ
る。The solvent for reacting the alkaline earth metal hexose phosphate and the neutral or acidic ferrous salt is preferably water, but water may coexist as long as it is a water-soluble solvent that does not interfere with the reaction. Typically, hexose phosphate g-iron salt is added to a 0.5-10% aqueous alkaline earth metal hexose phosphate solution with a concentration of 1-50%.
It is obtained by adding dropwise an aqueous ferrous salt solution and mixing. The reaction temperature is -10 to 70°C, preferably 10 to 40°C.
上記反応において副生ずる無機塩は水に難溶性の硫酸ノ
署すウム、炭酸バリウム、炭酸カルシュラムなどである
ことが好ましく、これらであれば濾過によシ容易に除去
できる。無機塩を除去した後のヘキソースリン酸第一鉄
塩の水溶液から、凍結乾燥などの方法、または水溶性溶
媒を添加し再沈後、沈殿を濾過乾燥するなどの方法によ
り、粉末状のヘキソースリン酸第一鉄塩を単離できる。The inorganic salt produced as a by-product in the above reaction is preferably poorly soluble in water, such as aluminum sulfate, barium carbonate, calcium carbonate, etc., and these can be easily removed by filtration. From an aqueous solution of ferrous hexose phosphate after removing inorganic salts, powdered hexose phosphorus can be obtained by a method such as freeze-drying, or by adding a water-soluble solvent, reprecipitating, and then filtering and drying the precipitate. Ferrous acid salts can be isolated.
ヘキソースリン酸第一鉄塩は、鉄供給剤として有用であ
シ、食品への添加物、錠剤、カプセル剤、ドリンク剤な
どの形態で投与することができ、貧血の改善、予防等に
効果が認められる。なお、本発明はヘキソースリン酸第
一鉄塩の投与する形態によって限定されるものではない
。Ferrous hexose phosphate is useful as an iron supplying agent, and can be administered in the form of food additives, tablets, capsules, drinks, etc., and is effective in improving and preventing anemia. Is recognized. Note that the present invention is not limited by the form in which the ferrous hexose phosphate is administered.
次に実施例を挙げ、本発明を更に詳しく説明する。 Next, the present invention will be explained in more detail with reference to Examples.
実施例Ｉ
Ｂａ（ＯＨ）ｚ ” ８ＨｉＯ１２，１？ （０゜０３
８５モル）を９００ｄの水に溶解し、この溶液に４重量
％グルコース−１−リン酸水溶液２５０ Ｆ （０，０
３８５モルンを加え２５Ｃで３０分間攪拌し中和する。Example I Ba(OH)z”8HiO12,1? (0°03
85 mol) in 900 d of water, and to this solution was added a 4% by weight glucose-1-phosphoric acid aqueous solution 250 F (0,0
Add 385 morn and stir at 25C for 30 minutes to neutralize.
この水溶液を窒素置換した後、窒素雰囲気下で塩交換を
おこなう。この水溶液に硫酸第一鉄・７Ｈｚ０ １０．
７ ｆ （０，０３８６モル）を１００ｄの水に溶解し
た溶液を゛加え２５℃で３０分間攪拌すると、白色沈殿
のＢａＳＯ４が生成する。遠心分離によシ白色沈殿を除
去し、得られた透明な緑青色の水溶液にエタノール２０
００ｍを加えると淡緑色の固体が沈殿する。窒素雰囲気
下で、沈殿を濾過しエタノールで洗浄した後、減圧乾燥
するとグルコース−１−リン酸第一鉄塩１１２ＨｓＯ９
，９ｔが得られた。元素分析、ＮＭＲ，ＩＲの分析結果
は以下の通シである。After replacing this aqueous solution with nitrogen, salt exchange is performed in a nitrogen atmosphere. Add ferrous sulfate to this aqueous solution at 7Hz 10.
A solution of 7f (0,0386 mol) dissolved in 100 d of water is added and stirred at 25°C for 30 minutes to form a white precipitate of BaSO4. The white precipitate was removed by centrifugation, and 20% of ethanol was added to the resulting clear green-blue aqueous solution.
When 00m is added, a pale green solid precipitates. Under a nitrogen atmosphere, the precipitate was filtered, washed with ethanol, and dried under reduced pressure to yield ferrous glucose-1-phosphate 112HsO9.
, 9t were obtained. The results of elemental analysis, NMR, and IR are as follows.
元素分析（分子式Ｃ５ＨｔｓＯｔｔＰＦｅとして）：Ｆ
ｅ Ｐ ＣＨ
分析値 １６．０ ８．７ ２０．２ ４．７理論値
１６．０ Ｂ、９ ２０．６ ４．３Ｈ−ＮＭ Ｒ（
６０ＭＨｚ ％ Ｄ２０溶媒）：δ
３．３〜３．５ｂ、２Ｈ
３，７〜４．Ｏｂ、４Ｈ
４，５〜４．６ｂ、ＩＨ
赤外線吸収スペクトル（ＫＢｒ法）：
波数（ｃｍ ） 強度 帰属
３３５０ 、Ｓ Ｏ−Ｈ伸縮２９３０
Ｍ Ｃ−Ｉ（伸縮２８４０
Ｍ Ｃ−Ｈ伸縮１６６０ Ｍ
８６０ Ｍ
本品中に含まれる第一鉄イオン、をＫＭｎＯｎ酸化還元
法で定量すると、１４．６％であった。Elemental analysis (as molecular formula C5HtsOttPFe): F
e P CH Analytical value 16.0 8.7 20.2 4.7 Theoretical value
16.0 B, 9 20.6 4.3H-NMR(
60MHz % D20 solvent): δ 3.3-3.5b, 2H 3,7-4. Ob, 4H 4,5-4.6b, IH Infrared absorption spectrum (KBr method): Wavenumber (cm) Intensity Attribution 3350, S O-H stretching 2930
M C-I (Stretching 2840
M C-H stretch 1660 M 860 M The ferrous ion contained in this product was quantified by the KMnOn redox method and found to be 14.6%.
実施例２
Ｂａ（ＯＨ）ｇ” ８Ｈ２０１２，１？ （０，０３８
５モル）を９００艷の水に溶解し、この溶液に４重量％
グルコース−６−リン酸水溶液２５０ ｔ （０，０３
８５モル）を加え２５℃で３０分間攪拌し中和する。Example 2 Ba(OH)g” 8H2012,1? (0,038
5 mol) was dissolved in 900 liters of water, and 4% by weight was added to this solution.
Glucose-6-phosphoric acid aqueous solution 250 t (0,03
85 mol) and stirred at 25°C for 30 minutes to neutralize.
この水溶液を窒素置換した後、窒素雰囲気下にて塩交換
をおこなう。この水溶液に硫酸第一鉄・７Ｈｚ０ １０
．７Ｐ（０，０３８５モル）を１００艷の水に溶解した
溶液を加え２５℃で３０分間攪拌すると、白色沈殿のＢ
ａＳＯ４が生成する。遠心分離によシ白色沈殿を除去し
、得られた透明な緑青色の水溶液にエタノール２０００
ｍを加えると淡緑色の固体が沈殿する。窒素雰囲気下で
、沈殿を濾過しエタノールで洗浄した後、減圧乾燥する
とグルコース−６−リン酸第一鉄塩・２ＨｚＯ１０，１
Ｆが得られる。元素分析結果は以下の通シである。After replacing this aqueous solution with nitrogen, salt exchange is performed in a nitrogen atmosphere. Add ferrous sulfate to this aqueous solution at 7Hz0 10
．． A solution of 7P (0,0385 mol) dissolved in 100 liters of water was added and stirred at 25°C for 30 minutes, resulting in a white precipitate of B.
aSO4 is produced. The white precipitate was removed by centrifugation, and the resulting transparent green-blue aqueous solution was diluted with 2000 ml of ethanol.
When m is added, a pale green solid precipitates. Under a nitrogen atmosphere, the precipitate was filtered, washed with ethanol, and dried under reduced pressure to yield glucose-6-ferrous phosphate 2HzO10,1
F is obtained. The results of elemental analysis are as follows.
元素分析（分子式Ｃ５ＨｔｓＯｎＰＦｅとして）：Ｆｅ
Ｐ ＣＨ
分析値 １６．３ ９．０ ２１．２ ４．１理論値
１６．０ ８．９． ２０．６ ４．３本品中に含まれ
る第一鉄イオンをＫＭｎＱ４酸化還元法で定量すると１
４．２％であった。Elemental analysis (as molecular formula C5HtsOnPFe): Fe
P CH Analytical value 16.3 9.0 21.2 4.1 Theoretical value
16.0 8.9. 20.6 4.3 When the ferrous ion contained in this product is determined by the KMnQ4 redox method, it is 1
It was 4.2%.
実施例３
Ｂａ（ＯＨ）＊１１８ＨｚＯ２３，２Ｆ （０，０７３
５モ／’）を１７００ｍの水に溶解し、この溶液に５重
量％グルコース−１，６−ゾリン酸水溶液２５０？（０
，０３６８モル）を加え２５℃で３０分間攪拌し中和す
る。この水溶液を窒素置換した後、窒素雰囲気下にて塩
交換をおこなう。この水溶液に硫酸第一鉄・７Ｈｓ０
２０．４Ｆ（０，０７３５−１＝ｋ）を２００１ｎｌの
水に溶解した溶液を加え２５℃で３０分間攪拌すると、
白色沈殿のＢａＳＯ４が生成する。遠心分離によシ白色
沈殿を除去し、得られた透明な緑青色の水溶液にエタノ
ール４０００ｄを加えると淡緑色の固体が沈殿する。窒
素雰囲気下で、沈殿を濾過しエタノールで洗浄した後、
減圧乾燥するとグルコース−１，６−ゾリン酸第一鉄塩
−３ＨｚＯ１２，４ｔが得られる。元素分析結果は以下
の通シである。Example 3 Ba(OH)*118HzO23,2F (0,073
5% by weight of glucose-1,6-zophosphoric acid aqueous solution was dissolved in 1700m of water, and 250% of a 5% by weight glucose-1,6-zophosphoric acid aqueous solution was added to this solution. (0
, 0368 mol) and stirred at 25°C for 30 minutes to neutralize. After replacing this aqueous solution with nitrogen, salt exchange is performed in a nitrogen atmosphere. Ferrous sulfate/7Hs0 is added to this aqueous solution.
A solution of 20.4F (0,0735-1=k) dissolved in 2001nl of water was added and stirred at 25°C for 30 minutes.
A white precipitate of BaSO4 is formed. The white precipitate was removed by centrifugation, and 4000 d of ethanol was added to the resulting clear green-blue aqueous solution to precipitate a pale green solid. After filtering the precipitate and washing it with ethanol under a nitrogen atmosphere,
Drying under reduced pressure yields 12,4t of ferrous glucose-1,6-zophosphate-3HzO. The results of elemental analysis are as follows.
元素分析（分子式Ｃ６Ｈ１６０１５Ｐ２Ｆｅ２として）
：Ｆｅ Ｐ ＣＨ
分析値 ２１．８ １１．９ １３．８ ３．０理論値
２２．３ １２．４ １４．３ ３．２本品中に含ま
れる第一鉄イオンをＫＭｎＯ４酸化還元法で定量すると
１７．２％であった。Elemental analysis (as molecular formula C6H16015P2Fe2)
:Fe P CH Analytical value 21.8 11.9 13.8 3.0 Theoretical value 22.3 12.4 14.3 3.2 The ferrous ion contained in this product was determined by the KMnO4 redox method. It was 17.2%.
実施例４
Ｂａ（ＯＨ）ｔ・８Ｈｔ０ １２．１Ｆ（０，０３８５
モル）を９００Ｗｔｔの水に溶解し、この溶液に４重量
％フルクトース−６−リン酸水溶液２５０ ｆ （０，
０３８５モル）を加え２５℃で′３０分間攪拌し中和す
る。Example 4 Ba(OH)t・8Ht0 12.1F (0,0385
mol) in 900 Wtt of water, and to this solution was added 250 f (0,
0385 mol) and stirred at 25°C for 30 minutes to neutralize.
この水溶液を窒素置換した後、窒素雰囲気下にて塩交換
をおこなう。この水溶液に硫酸第一鉄・７Ｈ２０１０，
７Ｆ （０，０３８５モル）を１００ゴの水に溶解した
溶液を加え２５℃で３０分間攪拌すると、白色沈殿のＢ
ａＳＯ４が生成する。遠心分離によシ白色沈殿を除去し
、得られた透明な緑青色の水溶液にエタノール２０００
ｍを加えると淡緑色の固体が沈殿する。窒素雰囲気下で
、沈殿を濾過しエタノールで洗浄した後、減圧乾燥する
とフルクトース−６−リン酸第一鉄塩・２Ｈ２０９，８
Ｖが得られる。元素分析結果は以下の通シである。After replacing this aqueous solution with nitrogen, salt exchange is performed in a nitrogen atmosphere. In this aqueous solution, ferrous sulfate 7H2010,
A solution of 7F (0,0385 mol) dissolved in 100 grams of water was added and stirred at 25°C for 30 minutes, resulting in a white precipitate of B.
aSO4 is produced. The white precipitate was removed by centrifugation, and the resulting transparent green-blue aqueous solution was diluted with 2000 ml of ethanol.
When m is added, a pale green solid precipitates. Under a nitrogen atmosphere, the precipitate was filtered, washed with ethanol, and dried under reduced pressure to yield fructose-6-ferrous phosphate 2H209,8.
V is obtained. The results of elemental analysis are as follows.
元素分析（分子式Ｃ６Ｈ１３０１１ＰＦｅとして）：Ｆ
ｅ Ｐ ＣＨ
分析値 １５．６ ８．５ １９．４ ４．１理論値
１６．０ ８．９ ２０．６ ４．３本品中に含まれる
第一鉄イオンをＫＭｎＯ４酸化還元法で定量すると１３
．３％であった。Elemental analysis (as molecular formula C6H13011PFe): F
e P CH Analytical value 15.6 8.5 19.4 4.1 Theoretical value
16.0 8.9 20.6 4.3 When the ferrous ion contained in this product is determined by KMnO4 redox method, it is 13
．． It was 3%.
実施例５
Ｂａ（ＯＨ）ｚ ・８Ｈｘ０ ２３．２ Ｆ （０，０
７３５モル）を１７００ ｔｎｌの水に溶解し、この溶
液に５重量％フルクトース−１，６−ゾリン酸水溶液２
５０２（０，０３６８モル）を加え２５℃で３０分間攪
拌し中和する。この水溶液を窒素置換した後、窒素雰囲
気下にて塩交換をおこなう。この水溶液に硫酸第一鉄−
７Ｈ＊０ ２０．４Ｆ（０，０７３５モル）を２００ゴ
の水に溶解した溶液を加え２５℃で３０分間攪拌すると
、白色沈殿のＢａＳＯ４が生成する。遠心分離によシ白
色沈殿を除去し、得られた透明な緑青色の水溶液にエタ
ノール４０００ｄを加えると淡緑色の固体が沈殿する。Example 5 Ba(OH)z ・8Hx0 23.2 F (0,0
735 mol) in 1700 tnl of water, and to this solution was added a 5% by weight fructose-1,6-zophosphoric acid aqueous solution 2
502 (0,0368 mol) was added and stirred at 25°C for 30 minutes to neutralize. After replacing this aqueous solution with nitrogen, salt exchange is performed in a nitrogen atmosphere. This aqueous solution contains ferrous sulfate.
A solution of 7H*0 20.4F (0,0735 mol) dissolved in 200 g of water is added and stirred at 25° C. for 30 minutes to form a white precipitate of BaSO4. The white precipitate was removed by centrifugation, and 4000 d of ethanol was added to the resulting clear green-blue aqueous solution to precipitate a pale green solid.
窒素雰囲気下で、沈殿を濾過しエタノールで洗浄した後
、減圧乾燥するとフルクトース−１，６−ゾリン酸第一
鉄塩・３ＨｓＯ１２，ＩＰが得られる。元素分析結果は
以下の通シである。Under a nitrogen atmosphere, the precipitate is filtered, washed with ethanol, and then dried under reduced pressure to obtain ferrous fructose-1,6-zophosphate 3HsO12,IP. The results of elemental analysis are as follows.
元素分析（分子式Ｃ３Ｈ１１１０１５ＰＩＩＦ ｅｘと
して）：Ｆｅ Ｐ ＣＨ
分析値 ２１．８ １１．９ １３．８ ３．０理論値
２２．．３ １２．４ １４．３ ３．２本品中に含
まれる第一鉄イオンをＫＭｎＯ４酸化還元法で定量する
と１８．５％であった。Elemental analysis (as molecular formula C3H111015PIIF ex): Fe P CH Analytical value 21.8 11.9 13.8 3.0 Theoretical value 22. ．． 3 12.4 14.3 3.2 The ferrous ion contained in this product was determined to be 18.5% by KMnO4 redox method.
実施例６
ＳＤ系ラット（雄性、６週令９体重３５０２前後、１群
１０匹）をグルコース−１−リン酸第一鉄塩を配合ある
いは非配合の粉末飼料で１０日間飼育したのち、同飼料
で飼育を続けながら毎日１回頚静脈よシ体重の約１／ｌ
ｏ。（約１．７５ ｍ ）の血液を２０日間採血して実
験的貧血状態を生ぜしめつつ、随時赤血球数、ヘマトク
リット値、ヘモグロビン値の測定を行なった。その結果
を第１図〜第３図に示す。Example 6 SD rats (male, 6 weeks old, 9 weight, around 3502 kg, 10 rats per group) were fed powdered feed with or without ferrous glucose-1-phosphate for 10 days, and then fed with the same feed. Approximately 1/l of the body weight is fed to the jugular vein once a day while being reared.
o. (approximately 1.75 m2) of blood was collected for 20 days to create an experimental anemia state, and the red blood cell count, hematocrit value, and hemoglobin value were measured from time to time. The results are shown in FIGS. 1 to 3.
なお本実験に用いた飼料組成は次の通シである。The feed composition used in this experiment was as follows.
第１図〜第３図から明らかなように、グルコース−１−
リ／酸第一鉄塩寺を加えると、貧血の予防効果が認めら
れた。As is clear from Figures 1 to 3, glucose-1-
Addition of ferrous phosphoric acid salt was found to be effective in preventing anemia.
実施例７
錠剤：
乳 糖 ８
０ ％コーンスクーチ ４結晶セ
ルロース １０カルボキシメチルセ
ルロース ３．５グルコース−１−リン酸第一
鉄塩 ２．５へマドクリット値が３０〜３５％
の貧血状態の２６〜３５才の女性１０名に上記組成の錠
剤（１錠０．５ ｔ ）を１日４錠１ケ月間服用させた
ところ、１ケ月後のへマドクリット値が全員３５〜４０
％となり貧血状態を大巾に改善することができた。Example 7 Tablet: Lactose 8
0% Corn Scooch 4 Crystalline cellulose 10 Carboxymethyl cellulose 3.5 Ferrous glucose-1-phosphate 2.5 Madcrit value is 30-35%
When 10 women aged 26 to 35 with anemia took 4 tablets of the above composition (0.5 t per tablet) per day for 1 month, all of them had hematocrit values of 35 to 40 after 1 month.
% and was able to significantly improve the anemia condition.
実施例８
カプセル剤：
中鎖脂肪酸トリクリセライド ８９．５％グルコ
ース−１−リン酸第一鉄塩 １０天然トコフエロ
ール ０．５上記各成分をよく混合し
、カプセル充填機で３００！宛充填し、カプセル剤を調
製した。このカプセル剤は１日３粒宛服用する。Example 8 Capsule: Medium-chain fatty acid tricryceride 89.5% Glucose-1-ferrous phosphate 10 Natural tocopherol 0.5 The above ingredients were mixed well and filled with a capsule filling machine. Capsules were prepared. Take 3 capsules per day.
実施例９
ドリンク剤：
リンゴ酢 １．０％クエ
ン酸 ０．３クエン酸ナトリ
ウム ０．３グラニユー糖
１２．０蜂 蜜
３．０エタノール
１．０グル；−クー１−リン酸第一鉄塩
１．０ドリンク・７レーバー ０
．３ミネラルウオーター ８１．１上
記、処方物を混合溶解し、均一なドリンク剤を得た。Example 9 Drink: Apple cider vinegar 1.0% citric acid 0.3 Sodium citrate 0.3 Granulated sugar
12.0 honey
3.0 ethanol
1.0 glu; -cou 1-ferrous phosphate salt
1.0 drink/7 labor 0
．． 3 Mineral water 81.1 The above formulations were mixed and dissolved to obtain a uniform drink.
試験例１
グルコース−１−リン酸第−鉄ｍ・２ ＨｚＯ（実施例
１）、グルコース−６−リン酸第一鉄塩・２Ｈ２０（実
施例２）及び硫酸第一鉄塩書７Ｈ２０の１チ水溶液を調
製した。グルコース−１−リン酸第一鉄塩・２Ｈ，Ｏ、
グルコース−６−リン酸第一鉄塩・２Ｈ！Ｏの１％水溶
液のｐＨはそれぞれ６．８．６゜９であった。硫酸第一
鉄塩・７ＨｚＯの１％水溶液は、ＮａＯＨ水溶液でｐＨ
６，８に調整した。各試料５０−を容量１００ｍの密閉
容器に入れ、２５℃にて放置した。水溶液の外観及び第
一鉄イオンの含有量の経口変化を表１に示す。なお第一
鉄イオンの定量はＫＭｎＯａ酸化還元法におこなった。Test Example 1 One sample of glucose-1-ferrous phosphate m2 HzO (Example 1), glucose-6-ferrous phosphate 2H20 (Example 2) and ferrous sulfate salt 7H20 An aqueous solution was prepared. Glucose-1-phosphate ferrous salt 2H,O,
Glucose-6-phosphate ferrous salt 2H! The pH of each 1% aqueous solution of O was 6.8.6°9. A 1% aqueous solution of ferrous sulfate salt at 7HzO is adjusted to pH with an aqueous NaOH solution.
Adjusted to 6.8. Each sample 50- was placed in a sealed container with a capacity of 100 m and left at 25°C. Table 1 shows the appearance of the aqueous solution and the oral changes in the ferrous ion content. The ferrous ion was determined by the KMnOa redox method.
゛ 表１ 第一鉄イオンの安定性
（注）（）内の数字は調製直後の第一鉄塩濃度を１００
とした場合の第一鉄イオンの残存率を示す。゛ Table 1 Stability of ferrous ion (Note) The numbers in parentheses indicate the concentration of ferrous salt immediately after preparation as 100
The residual rate of ferrous ions is shown below.
この結果から明らかなようにヘキソースリン酸第一鉄塩
はｐＨが中性の水溶液において、空気酸化を受けにくい
。As is clear from this result, ferrous hexose phosphate is not susceptible to air oxidation in an aqueous solution with a neutral pH.
第１図ないし第３図は、いずれもラットを実験的貧血状
態とした場合の血液成分の経口変化を示す図面で、この
うち、第１図は赤血球数、第２図はへマドクリット値、
第３図はヘモグロビン値の経口変化を示すものである。
ｍ−（辷−−：コントロール群
−・−ニゲルコース−１−リン酸第一鉄塩配合群
以上Figures 1 to 3 are diagrams showing oral changes in blood components when rats are subjected to experimental anemia. Figure 1 shows the number of red blood cells, Figure 2 shows the hematocrit value,
FIG. 3 shows oral changes in hemoglobin values. m-(辷--: Control group-- Nigelcose-1-ferrous phosphate salt combination group or higher)
Claims (1)
くは酸性の第一鉄塩を反応させることを特徴とするヘキ
ソースリン酸第一鉄塩の製造法。 ３、ヘキソースリン酸第一鉄塩を有効成分として含有す
る鉄供給剤。[Claims] 1. Ferrous hexose phosphate salt. 2. A method for producing a ferrous hexose phosphate, which comprises reacting an alkaline earth metal hexose phosphate with a neutral or acidic ferrous salt. 3. An iron supplying agent containing ferrous hexose phosphate as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6207787A JPH0696586B2 (en) | 1987-03-17 | 1987-03-17 | Hexose-ferric acid ferrous salt, method for producing the same, and iron supplier containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6207787A JPH0696586B2 (en) | 1987-03-17 | 1987-03-17 | Hexose-ferric acid ferrous salt, method for producing the same, and iron supplier containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63227598A true JPS63227598A (en) | 1988-09-21 |
| JPH0696586B2 JPH0696586B2 (en) | 1994-11-30 |
Family
ID=13189648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6207787A Expired - Fee Related JPH0696586B2 (en) | 1987-03-17 | 1987-03-17 | Hexose-ferric acid ferrous salt, method for producing the same, and iron supplier containing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0696586B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006097122A1 (en) * | 2005-03-16 | 2006-09-21 | Gnosis S.P.A. | Ferrous fructose-1,6-diphosphate, use, composition and process for the obtainment thereof |
| JP2007106775A (en) * | 1996-12-31 | 2007-04-26 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
-
1987
- 1987-03-17 JP JP6207787A patent/JPH0696586B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007106775A (en) * | 1996-12-31 | 2007-04-26 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
| WO2006097122A1 (en) * | 2005-03-16 | 2006-09-21 | Gnosis S.P.A. | Ferrous fructose-1,6-diphosphate, use, composition and process for the obtainment thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0696586B2 (en) | 1994-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU886750A3 (en) | Method of preparing metal ion complex with oligo-or polygalacturonic acids | |
| AU702073B2 (en) | Pharmaceutical composition containing selected lanthanum carbonate hydrates | |
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| CA2676146C (en) | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation | |
| US4415555A (en) | Composition and method for treating iron deficiency syndrome | |
| NZ576672A (en) | Iron (iii)-carbohydrate based phosphate adsorbent | |
| JPS6240288B2 (en) | ||
| IE54572B1 (en) | Pharmaceutically active succinylated proteins comprising iron | |
| JPS60120832A (en) | Acid salt of valproic acid | |
| US2848366A (en) | Non-hydrated ferrous fumarate and hematinic composition thereof | |
| DK2125847T3 (en) | The ligand-modified poly oxo-hydroxy-metalionmaterialer, uses thereof and methods of preparation thereof | |
| CN104402984B (en) | A kind of preparation method of the iron protein succinylate of high amount of iron load | |
| EP0040521B1 (en) | Antacid material based on magnesium aluminium hydroxide and the preparation thereof | |
| JP2005500978A (en) | Creatine / citric acid compound, process for producing the same and use thereof | |
| JPWO2018003531A1 (en) | Pyrroloquinoline quinone monosodium, method for producing the same, and composition containing the same | |
| JPS63227598A (en) | Hexose phosphoric acid ferrous salt, production thereof and iron-providing agent containing said salt | |
| JPH02262534A (en) | Bismuth-containing composition suitable for treatment and preparation thereof | |
| US2904573A (en) | Ferrous citrate complex | |
| HU227595B1 (en) | Metal complexes of polygalacturonic acid and their production | |
| RU2756322C1 (en) | Method for obtaining amorphous water-soluble salts of magnesium citrate | |
| DE1270540B (en) | Process for the preparation of water-soluble complex compounds of aliphatic oxycarboxylic acids | |
| KR0144442B1 (en) | Water soluble bithmuth compound and process of preparation forthereof | |
| JPH10182149A (en) | New calcium magnesium double carbonate, its production and antacid | |
| US4215143A (en) | Anti-ulcer pharmaceutical composition containing inositol hexasulfate aluminum or sodium aluminum salt as active ingredient | |
| US1954766A (en) | Medicinal phenol compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |